Adverse Effects of Ivermectin in Patients with Sars-Cov-2

Abstract

Through a literature review in high impact journals, it was determined that ivermectin, in addition to being a drug widely recognized for its ability to treat and control parasitic infections, has various relevant clinical actions, such as the possibility of eradicating onchocerciasis or "river blindness" Considering this fact as a triumph of humanity for the WHO in 2009. The broad-spectrum antiviral potential of this drug against a variety of RNA viruses is raised, due to its ability to specifically inhibit nuclear-mediated nuclear transport by α / β importine, capable of blocking the nuclear traffic of viral proteins. The proposed anti-SARS-CoV-2 action of ivermectin involves its binding to the IMPα / β1 heterodimer that will bind to the coronavirus burden protein causing the viral load to reduce the host cell's antiviral response, improving the patient's clinical conditions. Several clinical trials of the use of ivermectin in relation to COVID-19 have shown that this drug could produce a slight improvement in its symptoms, so this bibliographic review aims to determine the pharmacokinetics and adverse effects of ivermectin, as possible treatment of SARS-CoV-2.